Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
NurExone Biologic Inc. (NRXBF) had Income from Continuous Operations of $-1.40M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-1.40M |
|
-- |
|
-- |
|
$1.33M |
|
$-1.33M |
|
$-0.06M |
|
$-1.40M |
|
$-1.40M |
|
$-1.40M |
|
|
Income from Continuous Operations |
$-1.40M |
$-1.40M |
|
$-1.40M |
|
$-1.33M |
|
$-1.28M |
|
80.02M |
|
80.02M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$2.60M |
|
$0.76M |
|
$1.48M |
|
$4.08M |
|
$0.99M |
|
-- |
|
$0.34M |
|
$1.32M |
|
$2.76M |
|
$2.76M |
|
$2.76M |
|
90.68M |
|
| Cash Flow Statement Financials | |
$-4.51M |
|
$-0.06M |
|
$5.83M |
|
$0.70M |
|
$2.14M |
|
$1.44M |
|
$1.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.63 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-4.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-50.58% |
|
-50.58% |
|
-34.17% |
|
-50.58% |
|
$0.03 |
|
$-0.06 |
|
$-0.06 |
|